Literature DB >> 20237552

Drug discovery: inhibitors that activate.

Karen Cichowski, Pasi A Jänne.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20237552     DOI： 10.1038/464358a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

Authors:  Jean Philippe Arnault; Janine Wechsler; Bernard Escudier; Alain Spatz; Gorana Tomasic; Vincent Sibaud; Selim Aractingi; Jean-Didier Grange; Vichnou Poirier-Colame; David Malka; Jean-Charles Soria; Christine Mateus; Caroline Robert
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

2.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

3.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

4.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

5.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.

Authors:  Tsuneo Ikenoue; Yohko Hikiba; Fumihiko Kanai; Yasuo Tanaka; Jun Imamura; Takaaki Imamura; Miki Ohta; Hideaki Ijichi; Keisuke Tateishi; Takayuki Kawakami; Jun Aragaki; Masayuki Matsumura; Takao Kawabe; Masao Omata
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

6.  Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas.

Authors:  J M Spencer; S M Kahn; W Jiang; V A DeLeo; I B Weinstein
Journal:  Arch Dermatol       Date:  1995-07

7.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544

8.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962
  8 in total
  33 in total

1.  The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

Authors:  Theodore S Nowicki; Augustine L Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

Review 2.  BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors.

Authors:  Catherine J Wang; Isaac Brownell
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

Review 3.  Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.

Authors:  S Wu; R K Singh
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

4.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Authors:  Lisa Zimmer; Uwe Hillen; Elisabeth Livingstone; Mario E Lacouture; Klaus Busam; Richard D Carvajal; Friederike Egberts; Axel Hauschild; Mohammed Kashani-Sabet; Simone M Goldinger; Reinhard Dummer; Georgina V Long; Grant McArthur; André Scherag; Antje Sucker; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

5.  Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Authors:  Ronan J Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M Steinberg; John J Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

6.  Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.

Authors:  Jianqiang Wu; Eva Dombi; Edwin Jousma; R Scott Dunn; Diana Lindquist; Beverly M Schnell; Mi-Ok Kim; Aerang Kim; Brigitte C Widemann; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

7.  Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.

Authors:  K Connolly; D Brungs; E Szeto; R J Epstein
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

8.  The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth.

Authors:  Cibele Cardoso; Rodolfo B Serafim; Akinori Kawakami; Cristiano Gonçalves Pereira; Jason Roszik; Valeria Valente; Vinicius L Vazquez; David E Fisher; Enilza M Espreafico
Journal:  Pigment Cell Melanoma Res       Date:  2018-12-16       Impact factor: 4.693

9.  Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.

Authors:  Gerald S Falchook; Peter Rady; Sharon Hymes; Harrison P Nguyen; Stephen K Tyring; Victor G Prieto; David S Hong; Razelle Kurzrock
Journal:  JAMA Dermatol       Date:  2013-03       Impact factor: 10.282

10.  GDC-0879, a BRAFV600E Inhibitor, Protects Kidney Podocytes from Death.

Authors:  Jonas Sieber; Nicolas Wieder; Abbe Clark; Manuel Reitberger; Sofia Matan; Jeannine Schoenfelder; Jianming Zhang; Anna Mandinova; Joshua Adam Bittker; Juan Gutierrez; Ozan Aygün; Namrata Udeshi; Steven Carr; Peter Mundel; Andreas Werner Jehle; Anna Greka
Journal:  Cell Chem Biol       Date:  2017-12-14       Impact factor: 8.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.